Christopher Paul Davies · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 29 Sep 2014•North Wales (East and Central)

Published report and response evidence

This report’s concerns and statements found in recipients’ published responses. Statements are included even where no link to an individual concern is recorded. A link shows an evidence connection; it does not assign responsibility.

View original report
Concerns
2

Raised in this report

Recipients
1

Named on the report

Responses found
0

Of 1 recipient

Stated actions
0

Described in responses

Recipients and published responses

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Concerns raised2

  1. Failure to communicate the effects of caffeine and smoking changes on clozapine levels
    Part of recurring concern: Failure to identify clinically significant medication risksPart of recurring concern: Unreliable safety monitoring and guidance for clozapine treatment
  2. Failure to communicate the warning signs of clozapine toxicity
    Part of recurring concern: Failure to communicate clinically significant medication risks to patients
No response statements

No respondent-stated action or position is included in the published responses for this report.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Failure to communicate the effects of caffeine and smoking changes on clozapine levels

Wider context from the report

“He stated that although his son’s clozapine levels were being regularly monitored, at no point was he ever made aware of the possible interaction between caffeine or the cessation/reduction of smoking in relation to clozapine levels, nor was he made aware of the possible warning signs of toxicity. It was therefore felt that there should be greater emphasis placed on the sharing of this knowledge with users and with staff within the Community Mental Health Team. It was also felt that due to memory issues, patients should be regularly reminded of this information. ”

Is this part of a recurring concern?

Yes — Failure to identify clinically significant medication risks; Unreliable safety monitoring and guidance for clozapine treatment.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Failure to communicate the warning signs of clozapine toxicity

Wider context from the report

“He stated that although his son’s clozapine levels were being regularly monitored, at no point was he ever made aware of the possible interaction between caffeine or the cessation/reduction of smoking in relation to clozapine levels, nor was he made aware of the possible warning signs of toxicity. It was therefore felt that there should be greater emphasis placed on the sharing of this knowledge with users and with staff within the Community Mental Health Team. It was also felt that due to memory issues, patients should be regularly reminded of this information. ”

Is this part of a recurring concern?

Yes — Failure to communicate clinically significant medication risks to patients.

Open source report
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Data last updated 7 September 2026